Top

Published in:

Open Access 01-12-2016 | Review

Magnetic nanotherapeutics for dysregulated synaptic plasticity during neuroAIDS and drug abuse

Authors: Vidya Sagar, Venkata Subba Rao Atluri, Sudheesh Pilakka-Kanthikeel, Madhavan Nair

Published in: Molecular Brain | Issue 1/2016

Abstract

The human immunodeficiency virus (HIV) is a neurotropic virus. It induces neurotoxicity and subsequent brain pathologies in different brain cells. Addiction to recreational drugs remarkably affects the initiation of HIV infections and expedites the progression of acquired immunodeficiency syndrome (AIDS) associated neuropathogenesis. Symptoms of HIV-associated neurocognitive disorders (HAND) are noticed in many AIDS patients. At least 50 % of HIV diagnosed cases show one or other kind of neuropathological signs or symptoms during different stages of disease progression. In the same line, mild to severe neurological alterations are seen in at least 80 % autopsies of AIDS patients. Neurological illnesses weaken the connections between neurons causing significant altercations in synaptic plasticity. Synaptic plasticity alterations during HIV infection and recreational drug abuse are mediated by complex cellular phenomena involving changes in gene expression and subsequent loss of dendritic and spine morphology and physiology. New treatment strategies with ability to deliver drugs across blood-brain barrier (BBB) are being intensively investigated. In this context, magnetic nanoparticles (MNPs) based nanoformulations have shown significant potential for target specificity, drug delivery, drug release, and bioavailability of desired amount of drugs in non-invasive brain targeting. MNPs-based potential therapies to promote neuronal plasticity during HIV infection and recreational drug abuse are being developed.

Gonzalez RG, Cheng LL, Westmoreland SV, Sakaie KE, Becerra LR, Lee PL, et al. Early brain injury in the SIV-macaque model of AIDS. AIDS. 2000;14(18):2841–9.CrossRefPubMed

Gray F, Lescs MC, Keohane C, Paraire F, Marc B, Durigon M, et al. Early brain changes in HIV infection: neuropathological study of 11 HIV seropositive, non-AIDS cases. J Neuropathol Exp Neurol. 1992;51(2):177–85.CrossRefPubMed

Chiodi F, Sönnerborg A, Albert J, Gaines H, Norkrans G, Hagberg L, et al. Human immunodeficiency virus infection of the brain. J Neurol Sci. 1988;85(3):245–57. doi:10.1016/0022-510x(88)90184-0.CrossRefPubMed

Peluso R, Haase A, Stowring L, Edwards M, Ventura P. A Trojan Horse mechanism for the spread of visna virus in monocytes. Virology. 1985;147(1):231–6.CrossRefPubMed

Eugenin EA, Osiecki K, Lopez L, Goldstein H, Calderon TM, Berman JW. CCL2/monocyte chemoattractant protein-1 mediates enhanced transmigration of human immunodeficiency virus (HIV)-infected leukocytes across the blood–brain barrier: a potential mechanism of HIV-CNS invasion and NeuroAIDS. J Neurosci. 2006;26(4):1098–106. doi:10.1523/JNEUROSCI.3863-05.2006.CrossRefPubMed

Webster NL, Crowe SM. Matrix metalloproteinases, their production by monocytes and macrophages and their potential role in HIV-related diseases. J Leukoc Biol. 2006;80(5):1052–66. doi:10.1189/jlb.0306152.CrossRefPubMed

Williams DW, Eugenin EA, Calderon TM, Berman JW. Monocyte maturation, HIV susceptibility, and transmigration across the blood brain barrier are critical in HIV neuropathogenesis. J Leukoc Biol. 2012;91(3):401–15. doi:10.1189/jlb.0811394.CrossRefPubMedPubMedCentral

Conant K, Garzino-Demo A, Nath A, McArthur JC, Halliday W, Power C, et al. Induction of monocyte chemoattractant protein-1 in HIV-1 Tat-stimulated astrocytes and elevation in AIDS dementia. Proc Natl Acad Sci U S A. 1998;95(6):3117–21.CrossRefPubMedPubMedCentral

Nath A, Geiger J. Neurobiological aspects of human immunodeficiency virus infection: neurotoxic mechanisms. Prog Neurobiol. 1998;54(1):19–33.CrossRefPubMed

10.

Nath A. Human immunodeficiency virus (HIV) proteins in neuropathogenesis of HIV dementia. J Infect Dis. 2002;186 Suppl 2:S193–8. doi:10.1086/344528.CrossRefPubMed

11.

Sagar V, Pilakka-Kanthikeel S, Pottathil R, Saxena SK, Nair M. Towards nanomedicines for neuroAIDS. Rev Med Virol. 2014;24(2):103–24. doi:10.1002/rmv.1778.CrossRefPubMedPubMedCentral

12.

Catani MV, Corasaniti MT, Navarra M, Nistico G, Finazzi-Agro A, Melino G. gp120 induces cell death in human neuroblastoma cells through the CXCR4 and CCR5 chemokine receptors. J Neurochem. 2000;74(6):2373–9.CrossRefPubMed

13.

Kaul M, Lipton SA. The NMDA Receptor-Its Role in Neuronal Apoptosis and HIV-Associated Dementia. NeuroAIDS. 2000;3(6). http://aidscience.org/neuroaids/zones/articles/2000/11/NMDA/.

14.

Walsh KA, Megyesi JF, Wilson JX, Crukley J, Laubach VE, Hammond RR. Antioxidant protection from HIV-1 gp120-induced neuroglial toxicity. J Neuroinflammation. 2004;1(1):8. doi:10.1186/1742-2094-1-8.CrossRefPubMedPubMedCentral

15.

Wesselingh SL, Takahashi K, Glass JD, McArthur JC, Griffin JW, Griffin DE. Cellular localization of tumor necrosis factor mRNA in neurological tissue from HIV-infected patients by combined reverse transcriptase/polymerase chain reaction in situ hybridization and immunohistochemistry. J Neuroimmunol. 1997;74(1–2):1–8.CrossRefPubMed

16.

Persidsky Y, Buttini M, Limoges J, Bock P, Gendelman HE. An analysis of HIV-1-associated inflammatory products in brain tissue of humans and SCID mice with HIV-1 encephalitis. J Neurovirol. 1997;3(6):401–16.CrossRefPubMed

17.

Ullrich CK, Groopman JE, Ganju RK. HIV-1 gp120- and gp160-induced apoptosis in cultured endothelial cells is mediated by caspases. Blood. 2000;96(4):1438–42.PubMed

18.

Tran PB, Ren D, Miller RJ. The HIV-1 coat protein gp120 regulates cxcr4-mediated signaling in neural progenitor cells. J Neuroimmunol. 2005;160(1–2):68–76. doi:10.1016/j.jneuroim.2004.11.001.CrossRefPubMedPubMedCentral

19.

Khan MZ, Shimizu S, Patel JP, Nelson A, Le M-T, Mullen-Przeworski A, et al. Regulation of neuronal P53 activity by CXCR4. Mol Cell Neurosci. 2005;30(1):58–66. doi:10.1016/j.mcn.2005.05.007.CrossRefPubMedPubMedCentral

20.

Garden GA, Guo W, Jayadev S, Tun C, Balcaitis S, Choi J, et al. HIV associated neurodegeneration requires p53 in neurons and microglia. FASEB J. 2004;18(10):1141–3. doi:10.1096/fj.04-1676fje.PubMed

21.

Shin AH, Kim HJ, Thayer SA. Subtype selective NMDA receptor antagonists induce recovery of synapses lost following exposure to HIV-1 Tat. Br J Pharmacol. 2012;166(3):1002–17. doi:10.1111/j.1476-5381.2011.01805.x.CrossRefPubMedPubMedCentral

22.

Pingle SC, Jajoo S, Mukherjea D, Sniderhan LF, Jhaveri KA, Marcuzzi A, et al. Activation of the Adenosine A1 Receptor Inhibits HIV-1 Tat-Induced Apoptosis by Reducing Nuclear Factor-κB Activation and Inducible Nitric-Oxide Synthase. Mol Pharmacol. 2007;72(4):856–67. doi:10.1124/mol.106.031427.CrossRefPubMed

23.

Zauli G, Secchiero P, Rodella L, Gibellini D, Mirandola P, Mazzoni M, et al. HIV-1 Tat-mediated inhibition of the tyrosine hydroxylase gene expression in dopaminergic neuronal cells. J Biol Chem. 2000;275(6):4159–65.CrossRefPubMed

24.

Zhu J, Mactutus CF, Wallace DR, Booze RM. HIV-1 Tat protein-induced rapid and reversible decrease in [3H]dopamine uptake: dissociation of [3H]dopamine uptake and [3H]2beta-carbomethoxy-3-beta-(4-fluorophenyl)tropane (WIN 35,428) binding in rat striatal synaptosomes. J Pharmacol Exp Ther. 2009;329(3):1071–83. doi:10.1124/jpet.108.150144.CrossRefPubMedPubMedCentral

25.

Zhou BY, Liu Y, Kim B, Xiao Y, He JJ. Astrocyte activation and dysfunction and neuron death by HIV-1 Tat expression in astrocytes. Mol Cell Neurosci. 2004;27(3):296–305. doi:10.1016/j.mcn.2004.07.003.CrossRefPubMed

26.

Bokhari SM, Yao H, Bethel-Brown C, Fuwang P, Williams R, Dhillon NK, et al. Morphine enhances Tat-induced activation in murine microglia. J Neurovirol. 2009;15(3):219–28. doi:10.1080/13550280902913628.CrossRefPubMedPubMedCentral

27.

Price TO, Uras F, Banks WA, Ercal N. A novel antioxidant N-acetylcysteine amide prevents gp120- and Tat-induced oxidative stress in brain endothelial cells. Exp Neurol. 2006;201(1):193–202. doi:10.1016/j.expneurol.2006.03.030.CrossRefPubMed

28.

Mishra M, Taneja M, Malik S, Khalique H, Seth P. Human immunodeficiency virus type 1 Tat modulates proliferation and differentiation of human neural precursor cells: implication in NeuroAIDS. J Neurovirol. 2010;16(5):355–67. doi:10.3109/13550284.2010.513028.CrossRefPubMed

29.

Guha D, Nagilla P, Redinger C, Srinivasan A, Schatten GP, Ayyavoo V. Neuronal apoptosis by HIV-1 Vpr: contribution of proinflammatory molecular networks from infected target cells. J Neuroinflammation. 2012;9:138. doi:10.1186/1742-2094-9-138.CrossRefPubMedPubMedCentral

30.

Jones GJ, Barsby NL, Cohen EA, Holden J, Harris K, Dickie P, et al. HIV-1 Vpr causes neuronal apoptosis and in vivo neurodegeneration. J Neurosci. 2007;27(14):3703–11. doi:10.1523/JNEUROSCI.5522-06.2007.CrossRefPubMed

31.

Borgne-Sanchez A, Dupont S, Langonne A, Baux L, Lecoeur H, Chauvier D, et al. Targeted Vpr-derived peptides reach mitochondria to induce apoptosis of alphaVbeta3-expressing endothelial cells. Cell Death Differ. 2007;14(3):422–35. doi:10.1038/sj.cdd.4402018.CrossRefPubMed

32.

Piller SC, Ewart GD, Jans DA, Gage PW, Cox GB. The amino-terminal region of Vpr from human immunodeficiency virus type 1 forms ion channels and kills neurons. J Virol. 1999;73(5):4230–8.PubMedPubMedCentral

33.

Deshmane SL, Mukerjee R, Fan S, Del Valle L, Michiels C, Sweet T, et al. Activation of the oxidative stress pathway by HIV-1 Vpr leads to induction of hypoxia-inducible factor 1alpha expression. J Biol Chem. 2009;284(17):11364–73. doi:10.1074/jbc.M809266200.CrossRefPubMedPubMedCentral

34.

Kitayama H, Miura Y, Ando Y, Hoshino S, Ishizaka Y, Koyanagi Y. Human Immunodeficiency Virus Type 1 Vpr Inhibits Axonal Outgrowth through Induction of Mitochondrial Dysfunction. J Virol. 2008;82(5):2528–42. doi:10.1128/jvi.02094-07.CrossRefPubMedPubMedCentral

35.

Shi B, De Girolami U, He J, Wang S, Lorenzo A, Busciglio J, et al. Apoptosis induced by HIV-1 infection of the central nervous system. J Clin Invest. 1996;98(9):1979–90. doi:10.1172/JCI119002.CrossRefPubMedPubMedCentral

36.

Acheampong EA, Parveen Z, Muthoga LW, Kalayeh M, Mukhtar M, Pomerantz RJ. Human Immunodeficiency Virus Type 1 Nef Potently Induces Apoptosis in Primary Human Brain Microvascular Endothelial Cells via the Activation of Caspases. J Virol. 2005;79(7):4257–69. doi:10.1128/jvi.79.7.4257-4269.2005.CrossRefPubMedPubMedCentral

37.

Kort JJ, Jalonen TO. The nef protein of the human immunodeficiency virus type 1 (HIV-1) inhibits a large-conductance potassium channel in human glial cells. Neurosci Lett. 1998;251(1):1–4.CrossRefPubMed

38.

Olivetta E, Percario Z, Fiorucci G, Mattia G, Schiavoni I, Dennis C, et al. HIV-1 Nef induces the release of inflammatory factors from human monocyte/macrophages: involvement of Nef endocytotic signals and NF-kappa B activation. J Immunol. 2003;170(4):1716–27.CrossRefPubMed

39.

Meggendorfer M, Rothenaigner I, Tigges B, Vincendeau M, Brack-Werner R. Neurotoxicity of HIV-1 proteins. The Neurology of AIDS. New York: Oxford University Press; 2011.

40.

Agudelo M, Figueroa G, Yndart A, Casteleiro G, Munoz K, Samikkannu T, et al. Alcohol and Cannabinoids Differentially Affect HIV Infection and Function of Human Monocyte-Derived Dendritic Cells (MDDC). Front Microbiol. 2015;6:1452. doi:10.3389/fmicb.2015.01452.CrossRefPubMedPubMedCentral

41.

Cisneros IE, Ghorpade A. HIV-1, methamphetamine and astrocyte glutamate regulation: combined excitotoxic implications for neuro-AIDS. Curr HIV Res. 2012;10(5):392–406. doi:10.2174/157016212802138832.CrossRefPubMedPubMedCentral

42.

Rippeth JD, Heaton RK, Carey CL, Marcotte TD, Moore DJ, Gonzalez R, et al. Methamphetamine dependence increases risk of neuropsychological impairment in HIV infected persons. J Int Neuropsychol Soc. 2004;10(1):1–14. doi:10.1017/S1355617704101021.CrossRefPubMed

43.

Samikkannu T, Rao KV, Salam AA, Atluri VS, Kaftanovskaya EM, Agudelo M, et al. HIV Subtypes B and C gp120 and Methamphetamine Interaction: Dopaminergic System Implicates Differential Neuronal Toxicity. Sci Rep. 2015;5:11130. doi:10.1038/srep11130.CrossRefPubMedPubMedCentral

44.

Aksenov MY, Aksenova MV, Nath A, Ray PD, Mactutus CF, Booze RM. Cocaine-mediated enhancement of Tat toxicity in rat hippocampal cell cultures: the role of oxidative stress and D1 dopamine receptor. Neurotoxicology. 2006;27(2):217–28. doi:10.1016/j.neuro.2005.10.003.CrossRefPubMed

45.

Hauser KF, El-Hage N, Buch S, Nath A, Tyor WR, Bruce-Keller AJ, et al. Impact of opiate-HIV-1 interactions on neurotoxic signaling. J Neuroimmune Pharmacol. 2006;1(1):98–105. doi:10.1007/s11481-005-9000-4.CrossRefPubMed

46.

Nair MP, Chadha KC, Hewitt RG, Mahajan S, Sweet A, Schwartz SA. Cocaine differentially modulates chemokine production by mononuclear cells from normal donors and human immunodeficiency virus type 1-infected patients. Clin Diagn Lab Immunol. 2000;7(1):96–100.PubMedPubMedCentral

47.

Bagetta G, Piccirilli S, Del Duca C, Morrone LA, RombolÃ L, Nappi G, et al. Inducible nitric oxide synthase is involved in the mechanisms of cocaine enhanced neuronal apoptosis induced by HIV-1 gp120 in theneocortex of rat. Neurosci Lett. 2004;356(3):183–6. doi:10.1016/j.neulet.2003.11.065.CrossRefPubMed

48.

Yao H, Allen JE, Zhu X, Callen S, Buch S. Cocaine and human immunodeficiency virus type 1 gp120 mediate neurotoxicity through overlapping signaling pathways. J Neurovirol. 2009;15(2):164–75. doi:10.1080/13550280902755375.CrossRefPubMedPubMedCentral

49.

Buch S, Yao H, Roy S. HIV and cocaine. The Neurology of AIDS. New York: Oxford University Press; 2011.

50.

Riddle EL, Fleckenstein AE, Hanson GR. Mechanisms of methamphetamine-induced dopaminergic neurotoxicity. AAPS J. 2006;8(2):E413–8.CrossRefPubMedPubMedCentral

51.

Rogers TJ, Steele AD, Howard OM, Oppenheim JJ. Bidirectional heterologous desensitization of opioid and chemokine receptors. Ann N Y Acad Sci. 2000;917:19–28.CrossRefPubMed

52.

El-Hage N, Gurwell JA, Singh IN, Knapp PE, Nath A, Hauser KF. Synergistic increases in intracellular Ca2+, and the release of MCP-1, RANTES, and IL-6 by astrocytes treated with opiates and HIV-1 Tat. Glia. 2005;50(2):91–106. doi:10.1002/glia.20148.CrossRefPubMedPubMedCentral

53.

Reddy PV, Pilakka-Kanthikeel S, Saxena SK, Saiyed Z, Nair MP. Interactive Effects of Morphine on HIV Infection: Role in HIV-Associated Neurocognitive Disorder. AIDS Res Treat. 2012;2012:953678. doi:10.1155/2012/953678.PubMedPubMedCentral

54.

Cabran GA, Raborn ES. HIV-1 and Cannabinoids. The Neurology of AIDS. New York: Oxford University Press; 2011.

55.

Persidsky Y, Heilman D, Haorah J, Zelivyanskaya M, Persidsky R, Weber GA, et al. Rho-mediated regulation of tight junctions during monocyte migration across the blood–brain barrier in HIV-1 encephalitis (HIVE). Blood. 2006;107(12):4770–80. doi:10.1182/blood-2005-11-4721.CrossRefPubMedPubMedCentral

56.

Ellis R, Langford D, Masliah E. HIV and antiretroviral therapy in the brain: neuronal injury and repair. Nat Rev Neurosci. 2007;8(1):33–44. doi:10.1038/nrn2040.CrossRefPubMed

57.

Iskander S, Walsh KA, Hammond RR. Human CNS cultures exposed to HIV-1 gp120 reproduce dendritic injuries of HIV-1-associated dementia. J Neuroinflammation. 2004;1(1):7. doi:10.1186/1742-2094-1-7.CrossRefPubMedPubMedCentral

58.

Avdoshina V, Bachis A, Mocchetti I. Synaptic dysfunction in human immunodeficiency virus type-1-positive subjects: inflammation or impaired neuronal plasticity? J Intern Med. 2013;273(5):454–65. doi:10.1111/joim.12050.CrossRefPubMedPubMedCentral

59.

Atluri VS, Kanthikeel SP, Reddy PV, Yndart A, Nair MP. Human synaptic plasticity gene expression profile and dendritic spine density changes in HIV-infected human CNS cells: role in HIV-associated neurocognitive disorders (HAND). PLoS One. 2013;8(4):e61399. doi:10.1371/journal.pone.0061399.CrossRefPubMedPubMedCentral

60.

Samikkannu T, Atluri VSR, Arias AY, Rao KVK, Mulet CT, Jayant RD, et al. HIV-1 Subtypes B and C Tat Differentially Impact Synaptic Plasticity Expression and Implicates HIV-Associated Neurocognitive Disorders(). Curr HIV Res. 2014;12(6):397–405.CrossRefPubMedPubMedCentral

61.

Napolitano M, Marfia GA, Vacca A, Centonze D, Bellavia D, Di Marcotullio L, et al. Modulation of gene expression following long-term synaptic depression in the striatum. Mol Brain Res. 1999;72(1):89–96. doi:10.1016/S0169-328X(99)00213-2.CrossRefPubMed

62.

Atluri VS, Pilakka-Kanthikeel S, Samikkannu T, Sagar V, Kurapati KR, Saxena SK, et al. Vorinostat positively regulates synaptic plasticity genes expression and spine density in HIV infected neurons: role of nicotine in progression of HIV-associated neurocognitive disorder. Mol Brain. 2014;7:37. doi:10.1186/1756-6606-7-37.CrossRefPubMedPubMedCentral

63.

UNODC. World drug report 2014. Vienna: United Nations Office on Drugs and Crime; 2014. Available from: http://www.unodc.org/wdr2014/. Accessed on 5 May 2016.

64.

Sagar V, Pilakka-Kanthikeel S, Atluri VSR, Ding H, Arias AY, Jayant RD, et al. Therapeutical Neurotargeting via Magnetic Nanocarrier: Implications to Opiate-Induced Neuropathogenesis and NeuroAIDS. J Biomed Nanotechnol. 2015;11(10):1722–33.CrossRefPubMedPubMedCentral

65.

Atluri VS, Hernandez O, Hidalgo M, Kurapati KRV, Thangavel S, Kanthikeel SP, et al. Methamphetamine treatment and HIV-1 infection dysregulate Synaptic plasticity in SKNMC neuronal cells. J NeuroImmune Pharmacol. 2015;10(2):S59.

66.

Yndart A, Agudelo M, Raymond A, Atluri VSR, Munoz-Caamano K, Pilakka-Kanthikeel S, et al. Bath salts alter synaptic plasticity gene expression in neurons. J NeuroImmune Pharmacol. 2014;9(1):62.

67.

Ding H, Sagar V, Agudelo M, Pilakka-Kanthikeel S, Atluri VSR, Raymond A, et al. Enhanced blood–brain barrier transmigration using a novel Transferrin-embedded fluorescent magnetoliposome nanoformulation. Nanotechnology. 2014;25(5):055101. doi:10.1088/0957-4484/25/5/055101.CrossRefPubMedPubMedCentral

68.

Saiyed ZM, Gandhi NH, Nair MP. Magnetic nanoformulation of azidothymidine 5′-triphosphate for targeted delivery across the blood–brain barrier. Int J Nanomedicine. 2010;5:157–66.PubMedPubMedCentral

69.

Kaushik A, Jayant RD, Nikkhah-Moshaie R, Bhardwaj V, Roy U, Huang Z, et al. Magnetically guided central nervous system delivery and toxicity evaluation of magneto-electric nanocarriers. Sci Rep. 2016;6:25309.CrossRefPubMedPubMedCentral

70.

Escribano E, Fernandez-Pacheco R, Valdivia JG, Ibarra MR, Marquina C, Queralt J. Effect of magnet implant on iron biodistribution of Fe@C nanoparticles in the mouse. Arch Pharm Res. 2012;35(1):93–100. doi:10.1007/s12272-012-0109-8.CrossRefPubMed

71.

Nair M, Guduru R, Liang P, Hong J, Sagar V, Khizroev S. Externally controlled on-demand release of anti-HIV drug using magneto-electric nanoparticles as carriers. Nat Commun. 2013;4:1707.CrossRefPubMed

72.

Jayant RD, Atluri VSR, Agudelo M, Sagar V, Kaushik A, Nair M. Sustained-release nanoART formulation for the treatment of neuroAIDS. Int J Nanomedicine. 2015;10:1077–93. doi:10.2147/ijn.s76517.CrossRefPubMedPubMedCentral

73.

Fiandra L, Colombo M, Mazzucchelli S, Truffi M, Santini B, Allevi R, et al. Nanoformulation of antiretroviral drugs enhances their penetration across the blood brain barrier in mice. Nanomedicine. 2015;11(6):1387–97. doi:10.1016/j.nano.2015.03.009.PubMed

74.

Wen X, Wang K, Zhao Z, Zhang Y, Sun T, Zhang F, et al. Brain-targeted delivery of trans-activating transcriptor-conjugated magnetic PLGA/lipid nanoparticles. PLoS One. 2014;9(9):e106652. doi:10.1371/journal.pone.0106652.CrossRefPubMedPubMedCentral

75.

Raymond AD, Diaz P, Chevelon S, Agudelo M, Yndart-Arias A, Ding H, et al. Microglia-derived HIV Nef + exosome impairment of the blood–brain barrier is treatable by nanomedicine-based delivery of Nef peptides. Journal of neurovirology. 2015:1–11. doi:10.1007/s13365-015-0397-0

76.

Pilakka-Kanthikeel S, Atluri VSR, Sagar V, Saxena SK, Nair M. Targeted Brain Derived Neurotropic Factors (BDNF) Delivery across the Blood–brain Barrier for Neuro-Protection Using Magnetic Nano Carriers: An In-Vitro Study. PLoS One. 2013;8(4):e62241.CrossRefPubMedPubMedCentral

77.

Ortega-Gutiérrez S, Molina-Holgado E, Arévalo-Martín Á, Correa F, Viso A, López-Rodríguez ML, et al. Activation of the endocannabinoid system as therapeutic approach in a murine model of multiple sclerosis. FASEB J. 2005;19(10):1338–40. doi:10.1096/fj.04-2464fje.PubMed

78.

Venkata A, Pilakka-Kanthikeel S, Kurapati KR, Sagar V, Thangavel S, Ding H, et al. Role of HDAC2 and miR-485 in regulation of synaptic plasticity genes in HIV infection: Implication in HAND. J Neuroimmune Pharmacol. 2014;9(1):6.

79.

Vigorito M, Connaghan KP, Chang SL. The HIV-1 transgenic rat model of neuroHIV. Brain Behav Immun. 2015;48:336–49. doi:10.1016/j.bbi.2015.02.020.CrossRefPubMed

80.

Kong SD, Lee J, Ramachandran S, Eliceiri BP, Shubayev VI, Lal R, et al. Magnetic targeting of nanoparticles across the intact blood–brain barrier. J Control Release. 2015;164(1):49–57. doi:10.1016/j.jconrel.2012.09.021.CrossRef

81.

Tombacz E, Majzik A, Horvat ZS, Illes E. Magnetite in aqueous medium: Coating its surface and surface coated with it. Rom Rep Phys. 2006;58(3):281–6.

82.

Ghose SK, Petitto SC, Tanwar KS, Lo CS, Eng PJ, Chaka AM et al. Chapter 1 Surface Structure and Reactivity of Iron Oxide-Water Interfaces. Developments in Earth and Environmental Sciences. Amsterdam, The Netherlands: Elsevier; 2007. p. 1–29.

83.

Yoo HS, Lee EA, Park TG. Doxorubicin-conjugated biodegradable polymeric micelles having acid-cleavable linkages. J Control Release. 2002;82(1):17–27. doi:10.1016/S0168-3659(02)00088-3.CrossRefPubMed

84.

Wiogo HTR, Lim M, Bulmus V, Gutierrez L, Woodward RC, Amal R. Insight into Serum Protein Interactions with Functionalized Magnetic Nanoparticles in Biological Media. Langmuir. 2012;28(9):4346–56. doi:10.1021/la204740t.CrossRefPubMed

85.

Sagar V, Pilakka-Kanthikeel S, Ding H, Atluri VSR, Jayant RD, Kaushik A, et al. Novel magneto-electric nanodelivery of “microRNA mimic” across blood–brain barrier: Implications to cocaine modulation on HIV-associated neurocognitive disorders. J NeuroImmune Pharmacol. 2014;9(1):49.

86.

Kaushik A, Jayant RD, Sagar V, Nair M. The potential of magneto-electric nanocarriers for drug delivery. Expert Opin Drug Deliv. 2014;11(10):1635–46. doi:10.1517/17425247.2014.933803.CrossRefPubMedPubMedCentral

87.

Sagar VHZ, Kaushik A, Roy U, Jayant RD, Atluri VSR, Pilakka-Kanthikeel S, El-Haage N, Nair M. Effect of Magneto-electric nanoparticle on deep brain motor coordination activity. J NeuroImmune Pharmacol. 2015;10(S2):S99–S100. doi:10.1007/s11481-015-9596-y.

88.

Fusco S, Sakar MS, Kennedy S, Peters C, Bottani R, Starsich F, et al. An integrated microrobotic platform for on-demand, targeted therapeutic interventions. Adv Mater. 2013;26(6):952–7. doi:10.1002/adma.201304098.CrossRefPubMed

Title: Magnetic nanotherapeutics for dysregulated synaptic plasticity during neuroAIDS and drug abuse
Authors: Vidya Sagar
Venkata Subba Rao Atluri
Sudheesh Pilakka-Kanthikeel
Madhavan Nair
Publication date: 01-12-2016
Publisher: BioMed Central
Published in: Molecular Brain / Issue 1/2016
Electronic ISSN: 1756-6606
DOI: https://doi.org/10.1186/s13041-016-0236-0

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Magnetic nanotherapeutics for dysregulated synaptic plasticity during neuroAIDS and drug abuse

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2016

Two di-leucine motifs regulate trafficking and function of mouse ASIC2a

Nociceptive transmission and modulation via P2X receptors in central pain syndrome

A1 adenosine receptor attenuates intracerebral hemorrhage-induced secondary brain injury in rats by activating the P38-MAPKAP2-Hsp27 pathway

Astrocyte-secreted thrombospondin-1 modulates synapse and spine defects in the fragile X mouse model

Increased phosphorylation of collapsin response mediator protein-2 at Thr514 correlates with β-amyloid burden and synaptic deficits in Lewy body dementias

Linking F-box protein 7 and parkin to neuronal degeneration in Parkinson’s disease (PD)